Testing A New Treatment For Motor Neuron Disease

Grant number: 1005651 | Funding period: 2011 - 2013

Completed

Abstract

ALS is a form of motor neuron disease that quickly renders people paralysed by killing off the nerves needed for muscle control. It affects people when they are 40-60 years old, and very few survive more than 5 years after diagnosis. Our team is testing a new therapeutic compound that we have already shown to delay paralysis in mice with ALS. The work we are currently undertaking will provide all the necessary information required before we are able to test our compound in people with ALS.

Related publications (3)

Therapeutic effects of Cu-II(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis

Erin J McAllum, Nastasia K-H Lim, James L Hickey, Brett M Paterson, Paul S Donnelly, Qiao-Xin Li, Jeffrey R Liddell, Kevin J Barnham, Anthony R White, Peter J Crouch

2013-12-01

ALS-Associated TDP-43 Induces Endoplasmic Reticulum Stress, Which Drives Cytoplasmic TDP-43 Accumulation and Stress Granule Formation

Adam K Walker, Kai Y Soo, Vinod Sundaramoorthy, Sonam Parakh, Yi Ma, Manal A Farg, Robyn H Wallace, Peter J Crouch, Bradley J Turner, Malcolm K Horne, Julie D Atkin

2013-11-29

Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model

Theresa NT Dang, Carol Dobson-Stone, Elias N Glaros, Woojin S Kim, Marianne Hallupp, Lauren Bartley, Olivier Piguet, John R Hodges, Glenda M Halliday, Kay L Double, Peter R Schofield, Peter J Crouch, John BJ Kwok

2013-09-01